Larimar Therapeutics is a clinical-stage biotechnology company developing treatments for rare genetic diseases using a proprietary cell-penetrating peptide platform that enables therapeutic molecules to reach intracellular targets. The company's lead product, nomlabofusp, is a recombinant fusion protein designed to deliver frataxin to patients with Friedreich's ataxia, a rare progressive neurodegenerative disease with no existing therapies addressing its underlying protein deficiency. The company generates revenue through clinical development programs and plans to commercialize nomlabofusp directly or through partnerships while expanding its pipeline to additional rare diseases using its proprietary technology platform.